Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model
- PMID: 20214410
- DOI: 10.2165/11319350-000000000-00000
Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model
Abstract
For propofol clearance, allometric scaling has been applied successfully for extrapolations between species (rats and humans) and within the human bodyweight range (children and adults). In this analysis, the human bodyweight range is explored to determine for which range an allometric model with a fixed or estimated exponent can be used to predict propofol clearance, without correction for maturation. The predictive value of the allometric equation, clearance (CL) is equal to 0.071 x bodyweight in kg0.78, which was developed from rats, children and adults, and the predictive value of a fixed exponent allometric model derived from the basal metabolic rate, CL is equal to CL standardized to a 70 kg adult x (bodyweight in kg standardized to a 70 kg adult)0.75, were evaluated across five independent patient groups including (i) 25 (pre)term neonates with a postmenstrual age of 27-43 weeks; (ii) 22 postoperative infants aged 4-18 months; (iii) 12 toddlers aged 1-3 years; (iv) 14 adolescents aged 10-20 years; and (v) 26 critically ill adults sedated long term. The median percentage error of the predictions was calculated using the equation %error = (CL(allometric) - CL(i))/CL(i) x 100, where CL(allometric) is the predicted propofol clearance from the allometric equations for each individual and CL(i) is the individual-predicted (post hoc) propofol clearance value derived from published population pharmacokinetic models. In neonates, the allometric model developed from rats, children and adults, and the fixed-exponent allometric model, systematically overpredicted individual propofol clearance, with median percentage errors of 288% and 216%, respectively, whereas in infants, both models systematically underpredicted individual propofol clearance, with median percentage errors of -43% and -55%, respectively. In toddlers, adolescents and adults, both models performed reasonably well, with median percentage errors of -12% and -32%, respectively, in toddlers, 16% and -14%, respectively, in adolescents, and 12% and -18%, respectively, in adults. Both allometric models based on bodyweight alone may be of use to predict propofol clearance in individuals older than 2 years. Approaches that also incorporate maturation are required to predict clearance under the age of 2 years.
Similar articles
-
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.Pharm Res. 2012 Jun;29(6):1570-81. doi: 10.1007/s11095-012-0668-x. Pharm Res. 2012. PMID: 22287046 Free PMC article.
-
The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.Br J Clin Pharmacol. 2014 Jan;77(1):149-59. doi: 10.1111/bcp.12180. Br J Clin Pharmacol. 2014. PMID: 23772816 Free PMC article.
-
Evaluation of sigmoidal maturation and allometric models: prediction of propofol clearance in neonates and infants.Am J Ther. 2013 Jan;20(1):21-8. doi: 10.1519/JSC.0b013e31823b087a. Am J Ther. 2013. PMID: 23299229
-
Pediatric models for adult target-controlled infusion pumps.Paediatr Anaesth. 2010 Mar;20(3):223-32. doi: 10.1111/j.1460-9592.2009.03072.x. Epub 2009 Jul 13. Paediatr Anaesth. 2010. PMID: 19627530 Review.
-
Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Clin Pharmacokinet. 2018 Feb;57(2):125-149. doi: 10.1007/s40262-017-0569-6. Clin Pharmacokinet. 2018. PMID: 28688027 Free PMC article. Review.
Cited by
-
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.Pharm Res. 2012 Jun;29(6):1570-81. doi: 10.1007/s11095-012-0668-x. Pharm Res. 2012. PMID: 22287046 Free PMC article.
-
Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.Eur J Clin Pharmacol. 2019 Mar;75(3):381-392. doi: 10.1007/s00228-018-2600-8. Epub 2018 Nov 19. Eur J Clin Pharmacol. 2019. PMID: 30456415
-
A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.Clin Pharmacokinet. 2015 Mar;54(3):305-17. doi: 10.1007/s40262-014-0212-8. Clin Pharmacokinet. 2015. PMID: 25388986
-
Innovative clinical trial design for pediatric therapeutics.Expert Rev Clin Pharmacol. 2011 Sep;4(5):643-52. doi: 10.1586/ecp.11.43. Expert Rev Clin Pharmacol. 2011. PMID: 21980319 Free PMC article. Review.
-
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.J Pharmacokinet Pharmacodyn. 2022 Jun;49(3):293-310. doi: 10.1007/s10928-021-09791-8. Epub 2022 Jan 13. J Pharmacokinet Pharmacodyn. 2022. PMID: 35024995
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous